BrightEdge is assembling a portfolio of companies to attack cancer from every angle.
A novel approach to CAR T therapy
Developing novel cell engineering for in vivo CAR T
Immune activator intended to eliminate solid tumors
Developing immunotherapies designed to recognize and destroy tumor cells
Early stage venture capital fund
A technology VC fund that has a minority allocation to biotech and oncology.
Early detection via liquid biopsy
More accurately detecting cancer at earlier stages and define the tumor type to help oncologists select the best available treatment
Delivering next-gen T cell therapies
Developing diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. The company is focused on treating cancer, their first three targets are prostate, myeloma and ovarian.
Patient engagement & care management
A healthcare IT platform that allows for patients and their families to submit patient reported outcomes data to their oncology center in real time through the Company’s bidirectional interface with the oncology center’s EHR. Navigating Cancer’s proprietary predictive algorithm, allows for patients to be triaged so that interventions can occur when needed and the Company also distributes the right educational content to patients that has proven to improve compliance and adherence rates, and patient outcomes.
Precision medicine for melanoma
Develops and commercializes diagnostic and prognostic tests for dermatologic cancers. The tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions.